

Long-term safety and efficacy of lasmiditan for acute treatment of migraine with or without aura: results from the GLADIATOR study

Cephalalgia Reports

3, 251581632095817

DOI: [10.1177/2515816320958176](https://doi.org/10.1177/2515816320958176)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine. <i>Postgraduate Medicine</i> , 2021, 133, 449-459.	0.9	3
2	Lasmiditan: an additional therapeutic option for the acute treatment of migraine. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 491-502.	1.4	6
3	Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies. <i>Clinical Therapeutics</i> , 2021, 43, 1066-1078.	1.1	10
4	Lasmiditan for the acute treatment of migraine. <i>Pain Management</i> , 2021, 11, 437-449.	0.7	4
5	Budget impact of lasmiditan for the acute treatment of migraine in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1714-1723.	0.5	0
6	Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis. <i>Pain and Therapy</i> , 2022, 11, 701-712.	1.5	6
7	Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks. <i>Cephalalgia</i> , 2023, 43, 033310242211370.	1.8	8